Experimental Oncology, 2017, № 3http://dspace.nbuv.gov.ua:80/handle/123456789/1331762024-03-29T02:31:45Z2024-03-29T02:31:45ZContent of stem tumor CD133⁺ cells in brain neoplasms of different histological typeLisyaniy, N.I.Stanetskaya, D.N.Lisyaniy, A.N.Belskaya, L.N.http://dspace.nbuv.gov.ua:80/handle/123456789/1385442018-06-20T00:04:25Z2017-01-01T00:00:00ZContent of stem tumor CD133⁺ cells in brain neoplasms of different histological type
Lisyaniy, N.I.; Stanetskaya, D.N.; Lisyaniy, A.N.; Belskaya, L.N.
Today, there are conflicting data on the content of cancer stem cells responsible for recurrence and resistance to chemotherapy in tumors of human brain. The aim of the study was to analyze the content of CD133⁺cells in different brain tumors by immunofluorescence assay and immunohistochemical method. Materials and Methods: The samples of different brain tumors removed during neurosurgical operations were studied for CD133 expression. Results: Immunofluorescence assay of tumor imprints revealed CD133⁺cells in 40–85% of tumors regardless of histological type. In malignant tumors, the count of CD133⁺cells was higher than in benign tumors. Immunohistochemical method used for detection of CD133⁺cells was less sensitive than immunofluorescence technique. The number of CD133⁺cells may vary even in tumors of the same histological type. In 20–30% of malignant tumors (glioblastomas, medulloblastomas), the content of CD133⁺cells was very low or not detected at all. Conclusions: In tumors of the brain of different genesis and degree of anaplasia CD133⁺cells are found out. In malignant tumors (glioblastomas and medulloblastomas), CD133⁺cells are much more frequently detected than in benign brain tumors. The content of CD133⁺cells in brain tumors is highly variable being small and some malignant tumors, indicating low predictive and diagnostic value of cancer stem cell content in clinical practice.
2017-01-01T00:00:00ZPostnatal extra-embryonic tissues as a source of multiple cell types for regenerative medicine applicationsGubar, O.S.Rodnichenko, A.E.Vasyliev, R.G.Zlatska, A.V.Zubov, D.O.http://dspace.nbuv.gov.ua:80/handle/123456789/1385432018-06-20T00:05:30Z2017-01-01T00:00:00ZPostnatal extra-embryonic tissues as a source of multiple cell types for regenerative medicine applications
Gubar, O.S.; Rodnichenko, A.E.; Vasyliev, R.G.; Zlatska, A.V.; Zubov, D.O.
Aim: We aimed to isolate and characterize the cell types which could be obtained from postnatal extra-embryonic tissues. Materials and Methods: Fresh tissues (no more than 12 h after delivery) were used for enzymatic or explants methods of cell isolation. Obtained cultures were further maintained at 5% oxygen. At P3 cell phenotype was assessed by fluorescence-activated cell sorting, population doubling time was calculated and the multilineage differentiation assay was performed. Results: We have isolated multiple cell types from postnatal tissues. Namely, placental mesenchymal stromal cells from placenta chorionic disc, chorionic membrane mesenchymal stromal cells (ChM-MSC) from free chorionic membrane, umbilical cord MSC (UC-MSC) from whole umbilical cord, human umbilical vein endothelial cells (HUVEC) from umbilical vein, amniotic epithelial cells (AEC) and amniotic MSC (AMSC) from amniotic membrane. All isolated cell types displayed high proliferation rate together with the typical MSC phenotype: CD73⁺CD90⁺CD105⁺CD146⁺CD166⁺CD34⁻CD45⁻HLA⁻DR⁻. HUVEC constitutively expressed key markers CD31 and CD309. Most MSC and AEC were capable of osteogenic and adipogenic differentiation. Conclusion: We have shown that a wide variety of cell types can be easily isolated from extra-embryonic tissues and expanded ex vivo for regenerative medicine applications. These cells possess typical MSC properties and can be considered an alternative for adult MSC obtained from bone marrow or fat, especially for allogeneic use.
2017-01-01T00:00:00ZAre CD44⁺/CD24⁻ cells the assumed cancer stem cells in breast cancer?Ryspayeva, D.E.Smolanka, I.I.Dudnichenko, A.S.Lyashenko, A.A.Grinevich, Yu.A.Gurianov, V.G.Koshubarova, M.V.Seleznev, A.A.http://dspace.nbuv.gov.ua:80/handle/123456789/1385422018-06-20T00:05:15Z2017-01-01T00:00:00ZAre CD44⁺/CD24⁻ cells the assumed cancer stem cells in breast cancer?
Ryspayeva, D.E.; Smolanka, I.I.; Dudnichenko, A.S.; Lyashenko, A.A.; Grinevich, Yu.A.; Gurianov, V.G.; Koshubarova, M.V.; Seleznev, A.A.
Identification and characterization of the population of cancer stem cells (CSC) depends on several cellular markers, which combination is specific for the phenotype of CSC in the corresponding tumor. Several markers of CSC have already been identified in breast cancer (BC), but there are no universal indicators that could specifically identify the CSC in BC. Aims: To determine the validation of the CSC model for cell surface markers such as CD44 and CD24 and their clinical significance. Materials and Methods: Primary tumor samples of 45 patients with invasive BC without chemotherapy prior to surgery exposure were examined in paraffin blocks. CD44 and CD24 antigens expression was evaluated by the percentage of positive cells using different chromogens and the MultiVision detection system by immunohistochemical method. In this research the evaluation was determined by the following criteria: (-), negative — expression in < 10% of tumor cells; (+), positive — expression in ≥10% of cells. The same scoring system was applied for the expression of CD44⁺/CD24⁻. Results: 62.2% of investigated patients are patients older than 50 years and most of them with stage II of disease (71.0%) and luminal tumor subtypes (68.9%). We analysed the expression of CD44, CD24 and CD44⁺/CD24⁻ for different patients with dividing them into two groups. The group A consists of patients with unfavorable prognosis (relapses and metastases have occurred in the first three years after diagnosis), and the group B — with a favourable prognosis (the development of metastases after three years). Median disease-free survival in the group A is 19 months, in the group B — 46 months. The difference between the overall survival (OS) curves in the groups A and B is statistically significant (p < 0.001), the risk of death was higher in the group A (hazard ratio (HR) 5.9; confidence interval (CI) 2.3–15.2). The content of CD44 cells did not differ statistically between groups A and B (p = 0.18), but there was a tendency for increasing in OS with the existence of CD44+ cells (p = 0.056). The distribution of the expression of CD24 marker did not differ between the groups (p = 0.36) as well as the OS curves (p = 0.59). Analysis of the expression of CD44+/CD24⁻ which were considered as possible CSC, revealed a paradoxical increase (p = 0.03) of the frequency in patients of the group B (40.9%) compared to the group A (8.7%). Nevertheless, the comparison of the clinical outcomes did not reveal a statistically significant difference in the survival curves in the groups with existence and absence of CD44⁺/CD24⁻ expression (p = 0.08). The analysis showed the increasing of the risk of worse clinical outcomes in the cases of expression absence of CD44⁺/CD24⁻ (HR 2.8; CI 1.1–6.8). Conclusions: As a result of our research, the analysis of the quantity of assumed stem cells of the BC, which were identified by immunohistochemistry as CD44 and CD24 cells, failed to detect a statistically significant relation between groups of patients with different prognosis, and the identification of their expression is not enough for the characteristics of CSC. The obtained data demonstrating the worst clinical outcome in the cases of absence of CD44⁺/CD24⁻ expression apparently require further investigations and the validation of the immunohistochemical method with the determination of the cut-off line in defining of CD44 and CD24 status.
2017-01-01T00:00:00ZAnti-cancer efficiency of natural killer cells differentiated from human adipose tissue-derived mesenchymal stem cells and transfected with miRNA150Karlitepe, A.Kabadayi, H.Vatansever, S.Gurdal, M.Gunduz, C.Ercan, G.http://dspace.nbuv.gov.ua:80/handle/123456789/1385412018-06-21T00:03:43Z2017-01-01T00:00:00ZAnti-cancer efficiency of natural killer cells differentiated from human adipose tissue-derived mesenchymal stem cells and transfected with miRNA150
Karlitepe, A.; Kabadayi, H.; Vatansever, S.; Gurdal, M.; Gunduz, C.; Ercan, G.
Aim: The aim of this study is to investigate the effects of miR150 transfection on NK-like cells differentiated from adipose tissue derived mesenchymal stem cells (AD-MSCs). Methods: NK-like cells were differentiated from AD-MSCs and activated by miR150 transfection. Transfected/non-transfected NK-like cells were characterized by immunohistochemical and RTPCR analyzes. Apoptotic efficiency of the transfected/non-transfected NK-like cells on pancreatic cancer cells PANC1 were determined by TUNEL and RT-PCR. Results: In miR150-transfected cells, the increased expression of NK cell-specific genes such as GZMB, KIR2DL2, CD16, CD56, NKG2D, NKp46 and increased immunoreactivity of NK cell-specific surface marker CD314 (NKG2D) were evident. TUNEL assays showed that NK-like cells with/without transfection induced apoptosis in PANC1 cells in the same manner. The decrease in oncogene expression and the increase in the tumor suppressor gene expression in PANC1 cells upon co-culture with NK-like cells differentiated from AD-MSCs were more prominent following miRNA150 transfection. Conclusion: It was shown in vitro that NK-like cells could be obtained by differentiation from AD-MSCs and their efficiency could be increased via miR150 transfection. The results are encouraging for further clinical studies in improvement of immunotherapeutic approaches for cancer therapy.
2017-01-01T00:00:00Z